Infectious Causes of Rapidly Progressive Dementia

ABSTRACT

Infections represent an uncommon but important to recognize cause of rapidly progressive dementia, as diagnosis and treatment may produce a favorable outcome in selected instances. This article reviews infectious causes of rapidly progressive dementia, including selected viruses, bacteria, fungi, parasites, and prion diseases. Epidemiology, clinical manifestations, imaging characteristics, laboratory diagnosis, and treatment options are discussed.

KEYWORDS

Rapidly progressive dementia - infection

REFERENCES

• 1 Geschwind M D, Shu H, Haman A, Sejvar J J, Miller B L. Rapidly progressive dementia.  Ann Neurol. 2008;  64 (1) 97-108
• 2 Josephs K A, Ahlskog J E, Parisi J E et al.. Rapidly progressive neurodegenerative dementias.  Arch Neurol. 2009;  66 (2) 201-207
• 3 Bhaskaran K, Mussini C, Antinori A CASCADE Collaboration et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.  Ann Neurol. 2008;  63 (2) 213-221
• 4 Sacktor N, McDermott M P, Marder K et al.. HIV-associated cognitive impairment before and after the advent of combination therapy.  J Neurovirol. 2002;  8 (2) 136-142
• 5 Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force.  Neurology. 1991;  41 (6) 778-785
• 6 Antinori A, Arendt G, Becker J T et al.. Updated research nosology for HIV-associated neurocognitive disorders.  Neurology. 2007;  69 (18) 1789-1799
• 7 Cysique L A, Maruff P, Brew B J. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts.  J Neurovirol. 2004;  10 (6) 350-357
• 8 Dunlop O, Bjørklund R, Bruun J N et al.. Early psychomotor slowing predicts the development of HIV dementia and autopsy-verified HIV encephalitis.  Acta Neurol Scand. 2002;  105 (4) 270-275
• 9 Stern Y, McDermott M P, Albert S Dana Consortium on the Therapy of HIV-Dementia and Related Cognitive Disorders et al. Factors associated with incident human immunodeficiency virus-dementia.  Arch Neurol. 2001;  58 (3) 473-479
• 10 Navia B A, Price R W. The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection.  Arch Neurol. 1987;  44 (1) 65-69
• 11 Price R W, Brew B, Sidtis J, Rosenblum M, Scheck A C, Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex.  Science. 1988;  239 (4840) 586-592
• 12 McArthur J C, Brew B J, Nath A. Neurological complications of HIV infection.  Lancet Neurol. 2005;  4 (9) 543-555
• 13 Broderick D F, Wippold II F J, Clifford D B, Kido D, Wilson B S. White matter lesions and cerebral atrophy on MR images in patients with and without AIDS dementia complex.  AJR Am J Roentgenol. 1993;  161 (1) 177-181
• 14 Olsen W L, Longo F M, Mills C M, Norman D. White matter disease in AIDS: findings at MR imaging.  Radiology. 1988;  169 (2) 445-448
• 15 Thurnher M M, Thurnher S A, Schindler E. CNS involvement in AIDS: spectrum of CT and MR findings.  Eur Radiol. 1997;  7 (7) 1091-1097
• 16 Navia B A, Jordan B D, Price R W. The AIDS dementia complex: I. Clinical features.  Ann Neurol. 1986;  19 (6) 517-524
• 17 González-Scarano F, Martín-García J. The neuropathogenesis of AIDS.  Nat Rev Immunol. 2005;  5 (1) 69-81
• 18 Cysique L A, Vaida F, Letendre S et al.. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy.  Neurology. 2009;  73 (5) 342-348
• 19 Marra C M, Zhao Y, Clifford D B AIDS Clinical Trials Group 736 Study Team et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.  AIDS. 2009;  23 (11) 1359-1366
• 20 Sacktor N, Tarwater P M, Skolasky R L Multicenter for AIDS Cohort Study (MACS) et al. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing.  Neurology. 2001;  57 (3) 542-544
• 21 Robertson K R, Smurzynski M, Parsons T D et al.. The prevalence and incidence of neurocognitive impairment in the HAART era.  AIDS. 2007;  21 (14) 1915-1921
• 22 Tozzi V, Balestra P, Bellagamba R et al.. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors.  J Acquir Immune Defic Syndr. 2007;  45 (2) 174-182
• 23 Padgett B L, Walker D L, ZuRhein G M, Eckroade R J, Dessel B H. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy.  Lancet. 1971;  1 (7712) 1257-1260
• 24 Astrom K E, Mancall E L, Richardson Jr E P. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease.  Brain. 1958;  81 (1) 93-111
• 25 Tan C S, Koralnik I J. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.  Lancet Neurol. 2010;  9 (4) 425-437
• 26 Koralnik I J, Schellingerhout D, Frosch M P. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2004. A 66-year-old man with progressive neurologic deficits.  N Engl J Med. 2004;  350 (18) 1882-1893
• 27 Berger J R, Kaszovitz B, Post M J, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases.  Ann Intern Med. 1987;  107 (1) 78-87
• 28 Engsig F N, Hansen A B, Omland L H et al.. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study.  J Infect Dis. 2009;  199 (1) 77-83
• 29 Carson K R, Evens A M, Richey E A et al.. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.  Blood. 2009;  113 (20) 4834-4840
• 30 Korman B D, Tyler K L, Korman N J. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists.  Arch Dermatol. 2009;  145 (8) 937-942
• 31 Van Assche G, Van Ranst M, Sciot R et al.. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.  N Engl J Med. 2005;  353 (4) 362-368
• 32 García-Suárez J, de Miguel D, Krsnik I, Bañas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.  Am J Hematol. 2005;  80 (4) 271-281
• 33 Gheuens S, Pierone G, Peeters P, Koralnik I J. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression.  J Neurol Neurosurg Psychiatry. 2010;  81 (3) 247-254
• 34 Rockwell D, Ruben F L, Winkelstein A, Mendelow H. Absence of imune deficiencies in a case of progressive multifocal leukoencephalopathy.  Am J Med. 1976;  61 (3) 433-436
• 35 Lima M A, Drislane F W, Koralnik I J. Seizures and their outcome in progressive multifocal leukoencephalopathy.  Neurology. 2006;  66 (2) 262-264
• 36 Post M J, Yiannoutsos C, Simpson D et al.. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team.  AJNR Am J Neuroradiol. 1999;  20 (10) 1896-1906
• 37 Whiteman M L, Post M J, Berger J R, Tate L G, Bell M D, Limonte L P. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation.  Radiology. 1993;  187 (1) 233-240
• 38 Du Pasquier R A, Koralnik I J. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?.  J Neurovirol. 2003;  9 (Suppl 1) 25-31
• 39 Huang D, Cossoy M, Li M et al.. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients.  Ann Neurol. 2007;  62 (1) 34-39
• 40 Cinque P, Scarpellini P, Vago L, Linde A, Lazzarin A. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction.  AIDS. 1997;  11 (1) 1-17
• 41 Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Luca A. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy.  J Clin Microbiol. 2005;  43 (8) 4175-4177
• 42 Cinque P, Koralnik I J, Clifford D B. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology.  J Neurovirol. 2003;  9 (Suppl 1) 88-92
• 43 Kaplan J E, Benson C, Holmes K H, Brooks J T, Pau A, Masur H. Centers for Disease Control and Prevention (CDC) . Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.  MMWR Recomm Rep. 2009;  58 (RR-4) 1-207 quiz CE1-CE4
• 44 Crowder C D, Gyure K A, Drachenberg C B et al.. Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient.  Am J Transplant. 2005;  5 (5) 1151-1158
• 45 Vulliemoz S, Lurati-Ruiz F, Borruat F X et al.. Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis.  J Neurol Neurosurg Psychiatry. 2006;  77 (9) 1079-1082
• 46 Aksamit A J. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside.  J Neurovirol. 2001;  7 (4) 386-390
• 47 Lindå H, von Heijne A, Major E O et al.. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.  N Engl J Med. 2009;  361 (11) 1081-1087
• 48 Wenning W, Haghikia A, Laubenberger J et al.. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.  N Engl J Med. 2009;  361 (11) 1075-1080
• 49 Antinori A, Cingolani A, Lorenzini P Italian Registry Investigative Neuro AIDS Study Group et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA).  J Neurovirol. 2003;  9 (Suppl 1) 47-53
• 50 Levitz R E. Herpes simplex encephalitis: a review.  Heart Lung. 1998;  27 (3) 209-212
• 51 Whitley R J, Lakeman F. Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations.  Clin Infect Dis. 1995;  20 (2) 414-420
• 52 Fisher C M. Hypomanic symptoms caused by herpes simplex encephalitis.  Neurology. 1996;  47 (6) 1374-1378
• 53 Hart R P, Kwentus J A, Frazier R B, Hormel T L. Natural history of Klüver-Bucy syndrome after treated herpes encephalitis.  South Med J. 1986;  79 (11) 1376-1378
• 54 Domingues R B, Fink M C, Tsanaclis A M et al.. Diagnosis of herpes simplex encephalitis by magnetic resonance imaging and polymerase chain reaction assay of cerebrospinal fluid.  J Neurol Sci. 1998;  157 (2) 148-153
• 55 McCabe K, Tyler K, Tanabe J. Diffusion-weighted MRI abnormalities as a clue to the diagnosis of herpes simplex encephalitis.  Neurology. 2003;  61 (7) 1015-1016
• 56 Wasay M, Mekan S F, Khelaeni B et al.. Extra temporal involvement in herpes simplex encephalitis.  Eur J Neurol. 2005;  12 (6) 475-479
• 57 Misra U K, Kalita J. Neurophysiological studies in herpes simplex encephalitis.  Electromyogr Clin Neurophysiol. 1998;  38 (3) 177-182
• 58 Nahmias A J, Whitley R J, Visintine A N, Takei Y, Alford Jr C A. Herpes simplex virus encephalitis: laboratory evaluations and their diagnostic significance.  J Infect Dis. 1982;  145 (6) 829-836
• 59 Aurelius E, Johansson B, Sköldenberg B, Staland A, Forsgren M. Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid.  Lancet. 1991;  337 (8735) 189-192
• 60 DeBiasi R L, Kleinschmidt-DeMasters B K, Weinberg A, Tyler K L. Use of PCR for the diagnosis of herpesvirus infections of the central nervous system.  J Clin Virol. 2002;  25 (Suppl 1) S5-S11
• 61 Lakeman F D, Whitley R J. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group . Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease.  J Infect Dis. 1995;  171 (4) 857-863
• 62 Sköldenberg B, Forsgren M, Alestig K et al.. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients.  Lancet. 1984;  2 (8405) 707-711
• 63 Whitley R J, Alford C A, Hirsch M S et al.. Vidarabine versus acyclovir therapy in herpes simplex encephalitis.  N Engl J Med. 1986;  314 (3) 144-149
• 64 Gordon B, Selnes O A, Hart Jr J, Hanley D F, Whitley R J. Long-term cognitive sequelae of acyclovir-treated herpes simplex encephalitis.  Arch Neurol. 1990;  47 (6) 646-647
• 65 Bangen K J, Delano-Wood L, Wierenga C E, Stricker N H, Hesselink J R, Bondi M W. Dementia following herpes zoster encephalitis.  Clin Neuropsychol. 2010;  24 (7) 1193-1203
• 66 Valcour V, Haman A, Cornes S Vanderbilt Continuing Medical Education online et al. A case of enteroviral meningoencephalitis presenting as rapidly progressive dementia.  Nat Clin Pract Neurol. 2008;  4 (7) 399-403
• 67 Whitley R J, Cobbs C G, Alford Jr C A NIAD Collaborative Antiviral Study Group et al. Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome.  JAMA. 1989;  262 (2) 234-239
• 68 McNabb S J, Jajosky R A, Hall-Baker P A Centers for Disease Control and Prevention (CDC) et al. Summary of notifiable diseases—United States, 2006.  MMWR Morb Mortal Wkly Rep. 2008;  55 (53) 1-92
• 69 Reimann C A, Hayes E B, DiGuiseppi C et al.. Epidemiology of neuroinvasive arboviral disease in the United States, 1999-2007.  Am J Trop Med Hyg. 2008;  79 (6) 974-979
• 70 Nash D, Mostashari F, Fine A 1999 West Nile Outbreak Response Working Group et al. The outbreak of West Nile virus infection in the New York City area in 1999.  N Engl J Med. 2001;  344 (24) 1807-1814
• 71 Saad M, Youssef S, Kirschke D et al.. Acute flaccid paralysis: the spectrum of a newly recognized complication of West Nile virus infection.  J Infect. 2005;  51 (2) 120-127
• 72 Fishbein D B, Robinson L E. Rabies.  N Engl J Med. 1993;  329 (22) 1632-1638
• 73 Tyler K L. Emerging viral infections of the central nervous system: part 1.  Arch Neurol. 2009;  66 (8) 939-948
• 74 Morgello S, Cho E S, Nielsen S, Devinsky O, Petito C K. Cytomegalovirus encephalitis in patients with acquired immunodeficiency syndrome: an autopsy study of 30 cases and a review of the literature.  Hum Pathol. 1987;  18 (3) 289-297
• 75 Arribas J R, Storch G A, Clifford D B, Tselis A C. Cytomegalovirus encephalitis.  Ann Intern Med. 1996;  125 (7) 577-587
• 76 Eddleston M, Peacock S, Juniper M, Warrell D A. Severe cytomegalovirus infection in immunocompetent patients.  Clin Infect Dis. 1997;  24 (1) 52-56
• 77 McCutchan J A. Cytomegalovirus infections of the nervous system in patients with AIDS.  Clin Infect Dis. 1995;  20 (4) 747-754
• 78 Glaser C A, Honarmand S, Anderson L J et al.. Beyond viruses: clinical profiles and etiologies associated with encephalitis.  Clin Infect Dis. 2006;  43 (12) 1565-1577
• 79 Deresiewicz R L, Thaler S J, Hsu L, Zamani A A. Clinical and neuroradiographic manifestations of eastern equine encephalitis.  N Engl J Med. 1997;  336 (26) 1867-1874
• 80 Lury K M, Castillo M. Eastern equine encephalitis: CT and MRI findings in one case.  Emerg Radiol. 2004;  11 (1) 46-48
• 81 Misra U K, Kalita J. Overview: Japanese encephalitis.  Prog Neurobiol. 2010;  91 (2) 108-120
• 82 Petropoulou K A, Gordon S M, Prayson R A, Ruggierri P M. West Nile virus meningoencephalitis: MR imaging findings.  AJNR Am J Neuroradiol. 2005;  26 (8) 1986-1995
• 83 Kupila L, Vuorinen T, Vainionpää R, Hukkanen V, Marttila R J, Kotilainen P. Etiology of aseptic meningitis and encephalitis in an adult population.  Neurology. 2006;  66 (1) 75-80
• 84 Huang C, Morse D, Slater B et al.. Multiple-year experience in the diagnosis of viral central nervous system infections with a panel of polymerase chain reaction assays for detection of 11 viruses.  Clin Infect Dis. 2004;  39 (5) 630-635
• 85 Whitley R J, Gnann J W. Viral encephalitis: familiar infections and emerging pathogens.  Lancet. 2002;  359 (9305) 507-513
• 86 Tunkel A R, Glaser C A, Bloch K C Infectious Diseases Society of America et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America.  Clin Infect Dis. 2008;  47 (3) 303-327
• 87 Chong H T, Kamarulzaman A, Tan C T et al.. Treatment of acute Nipah encephalitis with ribavirin.  Ann Neurol. 2001;  49 (6) 810-813
• 88 Rahal J J, Anderson J, Rosenberg C, Reagan T, Thompson L L. Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study.  J Infect Dis. 2004;  190 (6) 1084-1087
• 89 Bellini W J, Rota J S, Lowe L E et al.. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized.  J Infect Dis. 2005;  192 (10) 1686-1693
• 90 Dyken P R, Cunningham S C, Ward L C. Changing character of subacute sclerosing panencephalitis in the United States.  Pediatr Neurol. 1989;  5 (6) 339-341
• 91 Garg R K. Subacute sclerosing panencephalitis.  J Neurol. 2008;  255 (12) 1861-1871
• 92 Gutierrez J, Issacson R S, Koppel B S. Subacute sclerosing panencephalitis: an update.  Dev Med Child Neurol. 2010;  52 (10) 901-907
• 93 Miyazaki M, Nishimura M, Toda Y, Saijo T, Mori K, Kuroda Y. Long-term follow-up of a patient with subacute sclerosing panencephalitis successfully treated with intrathecal interferon alpha.  Brain Dev. 2005;  27 (4) 301-303
• 94 Oguz K K, Celebi A, Anlar B. MR imaging, diffusion-weighted imaging and MR spectroscopy findings in acute rapidly progressive subacute sclerosing panencephalitis.  Brain Dev. 2007;  29 (5) 306-311
• 95 Tuncay R, Akman-Demir G, Gökyigit A et al.. MRI in subacute sclerosing panencephalitis.  Neuroradiology. 1996;  38 (7) 636-640
• 96 Praveen-kumar S, Sinha S, Taly A B et al.. Electroencephalographic and imaging profile in a subacute sclerosing panencephalitis (SSPE) cohort: a correlative study.  Clin Neurophysiol. 2007;  118 (9) 1947-1954
• 97 Lakshmi V, Malathy Y, Rao R R. Serodiagnosis of subacute sclerosing panencephalitis by enzyme linked immunosorbent assay.  Indian J Pediatr. 1993;  60 (1) 37-41
• 98 Risk W S, Haddad F S. The variable natural history of subacute sclerosing panencephalitis: a study of 118 cases from the Middle East.  Arch Neurol. 1979;  36 (10) 610-614
• 99 Gascon G G. International Consortium on Subacute Sclerosing Panencephalitis . Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): international multicenter study.  J Child Neurol. 2003;  18 (12) 819-827
• 100 Yalaz K, Anlar B, Oktem F et al.. Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis.  Neurology. 1992;  42 (3 Pt 1) 488-491
• 101 Lukehart S A, Hook III E W, Baker-Zander S A, Collier A C, Critchlow C W, Handsfield H H. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment.  Ann Intern Med. 1988;  109 (11) 855-862
• 102 Rolfs R T, Joesoef M R, Hendershot E F The Syphilis and HIV Study Group et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection.  N Engl J Med. 1997;  337 (5) 307-314
• 103 Ghanem K G. Review: Neurosyphilis: a historical perspective and review.  CNS Neurosci Ther. 2010;  16 e157-e168
• 104 Bash S, Hathout G M, Cohen S. Mesiotemporal T2-weighted hyperintensity: neurosyphilis mimicking herpes encephalitis.  AJNR Am J Neuroradiol. 2001;  22 (2) 314-316
• 105 Marra C M. Neurosyphilis.  Curr Neurol Neurosci Rep. 2004;  4 (6) 435-440
• 106 Timmermans M, Carr J. Neurosyphilis in the modern era.  J Neurol Neurosurg Psychiatry. 2004;  75 (12) 1727-1730
• 107 Lee J W, Wilck M, Venna N. Dementia due to neurosyphilis with persistently negative CSF VDRL.  Neurology. 2005;  65 (11) 1838
• 108 Johns D R, Tierney M, Felsenstein D. Alteration in the natural history of neurosyphilis by concurrent infection with the human immunodeficiency virus.  N Engl J Med. 1987;  316 (25) 1569-1572
• 109 Taylor M M, Aynalem G, Olea L M, He P, Smith L V, Kerndt P R. A consequence of the syphilis epidemic among men who have sex with men (MSM): neurosyphilis in Los Angeles, 2001-2004.  Sex Transm Dis. 2008;  35 (5) 430-434
• 110 Merritt H H, Adams R D, Solomon H C. Neurosyphilis. New York: Oxford University Press; 1946
• 111 Hart G. Syphilis tests in diagnostic and therapeutic decision making.  Ann Intern Med. 1986;  104 (3) 368-376
• 112 Workowski K A, Berman S. Centers for Disease Control and Prevention (CDC) . Sexually transmitted diseases treatment guidelines, 2010.  MMWR Recomm Rep. 2010;  59 (RR-12) 1-110
• 113 Luft B J, Steinman C R, Neimark H C et al.. Invasion of the central nervous system by Borrelia burgdorferi in acute disseminated infection.  JAMA. 1992;  267 (10) 1364-1367
• 114 Ackermann R, Rehse-Küpper B, Gollmer E, Schmidt R. Chronic neurologic manifestations of erythema migrans borreliosis.  Ann N Y Acad Sci. 1988;  539 16-23
• 115 Halperin J J, Pass H L, Anand A K, Luft B J, Volkman D J, Dattwyler R J. Nervous system abnormalities in Lyme disease.  Ann N Y Acad Sci. 1988;  539 24-34
• 116 Logigian E L, Kaplan R F, Steere A C. Chronic neurologic manifestations of Lyme disease.  N Engl J Med. 1990;  323 (21) 1438-1444
• 117 Halperin J J, Volkman D J, Wu P. Central nervous system abnormalities in Lyme neuroborreliosis.  Neurology. 1991;  41 (10) 1571-1582
• 118 Oksi J, Kalimo H, Marttila R J et al.. Inflammatory brain changes in Lyme borreliosis. A report on three patients and review of literature.  Brain. 1996;  119 (Pt 6) 2143-2154
• 119 Steinbach J P, Melms A, Skalej M, Dichgans J. Delayed resolution of white matter changes following therapy of B burgdorferi encephalitis.  Neurology. 2005;  64 (4) 758-759
• 120 Centers for Disease Control and Prevention (CDC) . Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease.  MMWR Morb Mortal Wkly Rep. 1995;  44 (31) 590-591
• 121 Wormser G P, Dattwyler R J, Shapiro E D et al.. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.  Clin Infect Dis. 2006;  43 (9) 1089-1134
• 122 Blanc F, Jaulhac B, Fleury M et al.. Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients.  Neurology. 2007;  69 (10) 953-958
• 123 Roos K L, Berger J R. Is the presence of antibodies in CSF sufficient to make a definitive diagnosis of Lyme disease?.  Neurology. 2007;  69 (10) 949-950
• 124 Nocton J J, Bloom B J, Rutledge B J et al.. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis.  J Infect Dis. 1996;  174 (3) 623-627
• 125 Halperin J J. Nervous system Lyme disease.  Infect Dis Clin North Am. 2008;  22 (2) 261-274 vi vi
• 126 Clyde Jr W A. Clinical overview of typical Mycoplasma pneumoniae infections.  Clin Infect Dis. 1993;  17 (Suppl 1) S32-S36
• 127 Luby J P. Pneumonia caused by Mycoplasma pneumoniae infection.  Clin Chest Med. 1991;  12 (2) 237-244
• 128 Koskiniemi M. CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review.  Clin Infect Dis. 1993;  17 (Suppl 1) S52-S57
• 129 Narita M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia.  J Infect Chemother. 2010;  16 (3) 162-169
• 130 Coelho M, Leite A, Revés A et al.. Mycoplasma pneumoniae causing nervous system lesion and SIADH in the absence of pneumonia.  Clin Neurol Neurosurg. 2004;  106 (2) 129-131
• 131 Bitnun A, Ford-Jones E, Blaser S, Richardson S. Mycoplasma pneumoniae ecephalitis.  Semin Pediatr Infect Dis. 2003;  14 (2) 96-107
• 132 Daxboeck F. Mycoplasma pneumoniae central nervous system infections.  Curr Opin Neurol. 2006;  19 (4) 374-378
• 133 Smith R, Eviatar L. Neurologic manifestations of Mycoplasma pneumoniae infections: diverse spectrum of diseases. A report of six cases and review of the literature.  Clin Pediatr (Phila). 2000;  39 (4) 195-201
• 134 Ben-Ami R, Ephros M, Avidor B et al.. Cat-scratch disease in elderly patients.  Clin Infect Dis. 2005;  41 (7) 969-974
• 135 Florin T A, Zaoutis T E, Zaoutis L B. Beyond cat scratch disease: widening spectrum of Bartonella henselae infection.  Pediatrics. 2008;  121 (5) e1413-e1425
• 136 Arisoy E S, Correa A G, Wagner M L, Kaplan S L. Hepatosplenic cat-scratch disease in children: selected clinical features and treatment.  Clin Infect Dis. 1999;  28 (4) 778-784
• 137 Baylor P, Garoufi A, Karpathios T, Lutz J, Mogelof J, Moseley D. Transverse myelitis in 2 patients with Bartonella henselae infection (cat scratch disease).  Clin Infect Dis. 2007;  45 (4) e42-e45
• 138 Cunningham E T, Koehler J E. Ocular bartonellosis.  Am J Ophthalmol. 2000;  130 (3) 340-349
• 139 Marra C M. Neurologic complications of Bartonella henselae infection.  Curr Opin Neurol. 1995;  8 (3) 164-169
• 140 Selby G, Walker G L. Cerebral arteritis in cat-scratch disease.  Neurology. 1979;  29 (10) 1413-1418
• 141 Spach D H, Panther L A, Thorning D R, Dunn J E, Plorde J J, Miller R A. Intracerebral bacillary angiomatosis in a patient infected with human immunodeficiency virus.  Ann Intern Med. 1992;  116 (9) 740-742
• 142 Marienfeld C B, Dicapua D B, Sze G K, Goldstein J M. Expressive aphasia as a presentation of encephalitis with Bartonella henselae infection in an immunocompetent adult.  Yale J Biol Med. 2010;  83 (2) 67-71
• 143 Singhal A B, Newstein M C, Budzik R et al.. Diffusion-weighted magnetic resonance imaging abnormalities in Bartonella encephalopathy.  J Neuroimaging. 2003;  13 (1) 79-82
• 144 Margileth A M. Recent advances in diagnosis and treatment of cat scratch disease.  Curr Infect Dis Rep. 2000;  2 (2) 141-146
• 145 Spach D H, Koehler J E. Bartonella-associated infections.  Infect Dis Clin North Am. 1998;  12 (1) 137-155
• 146 Fenollar F, Puéchal X, Raoult D. Whipple's disease.  N Engl J Med. 2007;  356 (1) 55-66
• 147 Martinetti M, Biagi F, Badulli C et al.. The HLA alleles DRB1*13 and DQB1*06 are associated to Whipple's disease.  Gastroenterology. 2009;  136 (7) 2289-2294
• 148 Marth T, Roux M, von Herbay A, Meuer S C, Feurle G E. Persistent reduction of complement receptor 3 alpha-chain expressing mononuclear blood cells and transient inhibitory serum factors in Whipple's disease.  Clin Immunol Immunopathol. 1994;  72 (2) 217-226
• 149 Moos V, Schmidt C, Geelhaar A et al.. Impaired immune functions of monocytes and macrophages in Whipple's disease.  Gastroenterology. 2010;  138 (1) 210-220
• 150 Raoult D, Birg M L, La Scola B et al.. Cultivation of the bacillus of Whipple's disease.  N Engl J Med. 2000;  342 (9) 620-625
• 151 Durand D V, Lecomte C, Cathébras P, Rousset H, Godeau P. Whipple disease. Clinical review of 52 cases. The SNFMI Research Group on Whipple Disease. Société Nationale Française de Médecine Interne.  Medicine (Baltimore). 1997;  76 (3) 170-184
• 152 Panegyres P K, Edis R, Beaman M, Fallon M. Primary Whipple's disease of the brain: characterization of the clinical syndrome and molecular diagnosis.  QJM. 2006;  99 (9) 609-623
• 153 Gerard A, Sarrot-Reynauld F, Liozon E et al.. Neurologic presentation of Whipple disease: report of 12 cases and review of the literature.  Medicine (Baltimore). 2002;  81 (6) 443-457
• 154 Louis E D, Lynch T, Kaufmann P, Fahn S, Odel J. Diagnostic guidelines in central nervous system Whipple's disease.  Ann Neurol. 1996;  40 (4) 561-568
• 155 Matthews B R, Jones L K, Saad D A, Aksamit A J, Josephs K A. Cerebellar ataxia and central nervous system Whipple disease.  Arch Neurol. 2005;  62 (4) 618-620
• 156 Schneider T, Moos V, Loddenkemper C, Marth T, Fenollar F, Raoult D. Whipple's disease: new aspects of pathogenesis and treatment.  Lancet Infect Dis. 2008;  8 (3) 179-190
• 157 Cohen L, Berthet K, Dauga C, Thivart L, Pierrot-Deseilligny C. Polymerase chain reaction of cerebrospinal fluid to diagnose Whipple's disease.  Lancet. 1996;  347 (8997) 329
• 158 von Herbay A, Ditton H J, Schuhmacher F, Maiwald M. Whipple's disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebrospinal fluid.  Gastroenterology. 1997;  113 (2) 434-441
• 159 Elad Y, Nelson P J, Meier D E. Clinical problem-solving. Jumping to the wrong conclusion.  N Engl J Med. 1998;  339 (19) 1382-1387
• 160 Heckman G A, Hawkins C, Morris A, Burrows L L, Bergeron C. Rapidly progressive dementia due to Mycobacterium neoaurum meningoencephalitis.  Emerg Infect Dis. 2004;  10 (5) 924-927
• 161 Porta-Etessam J, Martínez-Salio A, Berbel A et al.. [Thalamic dementia due to infarct of the left thalamus and genum of the right internal capsule].  Rev Neurol. 2001;  33 (11) 1043-1046
• 162 Bahemuka M, Murungi J H. Tuberculosis of the nervous system. A clinical, radiological and pathological study of 39 consecutive cases in Riyadh, Saudi Arabia.  J Neurol Sci. 1989;  90 (1) 67-76
• 163 Berenguer J, Moreno S, Laguna F et al.. Tuberculous meningitis in patients infected with the human immunodeficiency virus.  N Engl J Med. 1992;  326 (10) 668-672
• 164 Talati N J, Rouphael N, Kuppalli K, Franco-Paredes C. Spectrum of CNS disease caused by rapidly growing mycobacteria.  Lancet Infect Dis. 2008;  8 (6) 390-398
• 165 Kennedy D H, Fallon R J. Tuberculous meningitis.  JAMA. 1979;  241 (3) 264-268
• 166 Kent S J, Crowe S M, Yung A, Lucas C R, Mijch A M. Tuberculous meningitis: a 30-year review.  Clin Infect Dis. 1993;  17 (6) 987-994
• 167 Streptomycin treatment of tuberculous meningitis.  Lancet. 1948;  1 (6503) 582-596
• 168 Ozateş M, Kemaloglu S, Gürkan F, Ozkan U, Hoşoglu S, Simşek M M. CT of the brain in tuberculous meningitis. A review of 289 patients.  Acta Radiol. 2000;  41 (1) 13-17
• 169 Bernaerts A, Vanhoenacker F M, Parizel P M et al.. Tuberculosis of the central nervous system: overview of neuroradiological findings.  Eur Radiol. 2003;  13 (8) 1876-1890
• 170 Karandanis D, Shulman J A. Recent survey of infectious meningitis in adults: review of laboratory findings in bacterial, tuberculous, and aseptic meningitis.  South Med J. 1976;  69 (4) 449-457
• 171 Thwaites G E, Chau T T, Farrar J J. Improving the bacteriological diagnosis of tuberculous meningitis.  J Clin Microbiol. 2004;  42 (1) 378-379
• 172 Noordhoek G T, Kolk A H, Bjune G et al.. Sensitivity and specificity of PCR for detection of Mycobacterium tuberculosis: a blind comparison study among seven laboratories.  J Clin Microbiol. 1994;  32 (2) 277-284
• 173 Bonington A, Strang J I, Klapper P E et al.. Use of Roche AMPLICOR Mycobacterium tuberculosis PCR in early diagnosis of tuberculous meningitis.  J Clin Microbiol. 1998;  36 (5) 1251-1254
• 174 Blumberg H M, Burman W J, Chaisson R E American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.  Am J Respir Crit Care Med. 2003;  167 (4) 603-662
• 175 Joint Tuberculosis Committee of the British Thoracic Society . Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998.  Thorax. 1998;  53 (7) 536-548
• 176 Thwaites G E, Lan N T, Dung N H et al.. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis.  J Infect Dis. 2005;  192 (1) 79-88
• 177 Thwaites G E, Nguyen D B, Nguyen H D et al.. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.  N Engl J Med. 2004;  351 (17) 1741-1751
• 178 Schoeman J F, Van Zyl L E, Laubscher J A, Donald P R. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis.  Pediatrics. 1997;  99 (2) 226-231
• 179 Jarvis J N, Harrison T S. HIV-associated cryptococcal meningitis.  AIDS. 2007;  21 (16) 2119-2129
• 180 Pappas P G, Perfect J R, Cloud G A et al.. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.  Clin Infect Dis. 2001;  33 (5) 690-699
• 181 Singh N, Lortholary O, Dromer F Cryptococcal Collaborative Transplant Study Group et al. Central nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings.  Transplantation. 2008;  86 (5) 647-651
• 182 Cox G M, Perfect J R. Cryptococcus neoformans var neoformans and gattii and Trichosporon species. In: Edward L A, ed. Topley and Wilson's Microbiology and Microbial Infections. 9th ed. London: Arnold Press; 1997
• 183 Ala T A, Doss R C, Sullivan C J. Reversible dementia: a case of cryptococcal meningitis masquerading as Alzheimer's disease.  J Alzheimers Dis. 2004;  6 (5) 503-508
• 184 Prakash P Y, Sugandhi R P. Neuropsychiatric manifestation of confusional psychosis due to Cryptococcus neoformans var. grubii in an apparently immunocompetent host: a case report.  Cases J. 2009;  2 9084
• 185 Sa'adah M A, Araj G F, Diab S M, Nazzal M. Cryptococcal meningitis and confusional psychosis. A case report and literature review.  Trop Geogr Med. 1995;  47 (5) 224-226
• 186 Steiner I, Polacheck I, Melamed E. Dementia and myoclonus in a case of cryptococcal encephalitis.  Arch Neurol. 1984;  41 (2) 216-217
• 187 Charlier C, Dromer F, Lévêque C et al.. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era.  PLoS One. 2008;  3 (4) e1950
• 188 Sánchez-Portocarrero J, Pérez-Cecilia E. Intracerebral mass lesions in patients with human immunodeficiency virus infection and cryptococcal meningitis.  Diagn Microbiol Infect Dis. 1997;  29 (3) 193-198
• 189 Park M K, Hospenthal D R, Bennett J E. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting.  Clin Infect Dis. 1999;  28 (3) 629-633
• 190 Wilcox R A, Thyagarajan D, Kempster P. Two cases of Cryptococcus meningitis presenting as leukoencephalopathy prior to amphotericin therapy.  Eur J Neurol. 2007;  14 (3) 350-352
• 191 Darras-Joly C, Chevret S, Wolff M et al.. Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus.  Clin Infect Dis. 1996;  23 (2) 369-376
• 192 Shaunak S, Schell W A, Perfect J R. Cryptococcal meningitis with normal cerebrospinal fluid.  J Infect Dis. 1989;  160 (5) 912
• 193 Diamond R D, Bennett J E. Prognostic factors in cryptococcal meningitis. A study in 111 cases.  Ann Intern Med. 1974;  80 (2) 176-181
• 194 Dismukes W E, Cloud G, Gallis H A et al.. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.  N Engl J Med. 1987;  317 (6) 334-341
• 195 Tanner D C, Weinstein M P, Fedorciw B, Joho K L, Thorpe J J, Reller L. Comparison of commercial kits for detection of cryptococcal antigen.  J Clin Microbiol. 1994;  32 (7) 1680-1684
• 196 Perfect J R, Dismukes W E, Dromer F et al.. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.  Clin Infect Dis. 2010;  50 (3) 291-322
• 197 Bach M C, Tally P W, Godofsky E W. Use of cerebrospinal fluid shunts in patients having acquired immunodeficiency syndrome with cryptococcal meningitis and uncontrollable intracranial hypertension.  Neurosurgery. 1997;  41 (6) 1280-1282, discussion 1282–1283
• 198 Bach M C, Armstrong R M. Acute toxoplasmic encephalitis in a normal adult.  Arch Neurol. 1983;  40 (9) 596-597
• 199 Habek M, Ozretić D, Zarković K, Djaković V, Mubrin Z. Unusual cause of dementia in an immunocompetent host: toxoplasmic encephalitis.  Neurol Sci. 2009;  30 (1) 45-49
• 200 Tenter A M, Heckeroth A R, Weiss L M. Toxoplasma gondii: from animals to humans.  Int J Parasitol. 2000;  30 (12-13) 1217-1258
• 201 Porter S B, Sande M A. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome.  N Engl J Med. 1992;  327 (23) 1643-1648
• 202 Ciricillo S F, Rosenblum M L. Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients.  J Neurosurg. 1990;  73 (5) 720-724
• 203 Kumar G G, Mahadevan A, Guruprasad A S et al.. Eccentric target sign in cerebral toxoplasmosis: neuropathological correlate to the imaging feature.  J Magn Reson Imaging. 2010;  31 (6) 1469-1472
• 204 Masamed R, Meleis A, Lee E W, Hathout G M. Cerebral toxoplasmosis: case review and description of a new imaging sign.  Clin Radiol. 2009;  64 (5) 560-563
• 205 Luft B J, Brooks R G, Conley F K, McCabe R E, Remington J S. Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome.  JAMA. 1984;  252 (7) 913-917
• 206 Lejon V, Boelaert M, Jannin J, Moore A, Büscher P. The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa.  Lancet Infect Dis. 2003;  3 (12) 804-808
• 207 Kennedy P G. Diagnostic and neuropathogenesis issues in human African trypanosomiasis.  Int J Parasitol. 2006;  36 (5) 505-512
• 208 Rodgers J. Human African trypanosomiasis, chemotherapy and CNS disease.  J Neuroimmunol. 2009;  211 (1-2) 16-22
• 209 Rodgers J. Trypanosomiasis and the brain.  Parasitology. 2010;  137 (14) 1995-2006
• 210 Chimelli L, Scaravilli F. Trypanosomiasis.  Brain Pathol. 1997;  7 (1) 599-611
• 211 Wéry M, Mulumba P M, Lambert P H, Kazyumba L. Hematologic manifestations, diagnosis, and immunopathology of African trypanosomiasis.  Semin Hematol. 1982;  19 (2) 83-92
• 212 Radwanska M. Emerging trends in the diagnosis of human African Trypanosomiasis.  Parasitology. 2010;  137 (14) 1977-1986
• 213 Simarro P P, Ruiz J A, Franco J R, Josenando T. Attitude towards CATT-positive individuals without parasitological confirmation in the African Trypanosomiasis (T.b. gambiense) focus of Quiçama (Angola).  Trop Med Int Health. 1999;  4 (12) 858-861
• 214 Truc P, Aerts D, McNamara J J et al.. Direct isolation in vitro of Trypanosoma brucei from man and other animals, and its potential value for the diagnosis of Gambian trypanosomiasis.  Trans R Soc Trop Med Hyg. 1992;  86 (6) 627-629
• 215 Lejon V, Sindic C J, Van Antwerpen M P et al.. Human African trypanosomiasis: quantitative and qualitative assessment of intrathecal immune response.  Eur J Neurol. 2003;  10 (6) 711-719
• 216 Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee.  World Health Organ Tech Rep Ser. 1998;  881 I-VI, 1–114
• 217 Braakman H M, van de Molengraft F J, Hubert W W, Boerman D H. Lethal African trypanosomiasis in a traveler: MRI and neuropathology.  Neurology. 2006;  66 (7) 1094-1096
• 218 Kager P A, Schipper H G, Stam J, Majoie C B. Magnetic resonance imaging findings in human African trypanosomiasis: a four-year follow-up study in a patient and review of the literature.  Am J Trop Med Hyg. 2009;  80 (6) 947-952
• 219 Kennedy P G. Human African trypanosomiasis of the CNS: current issues and challenges.  J Clin Invest. 2004;  113 (4) 496-504
• 220 Bisser S, N'Siesi F X, Lejon V et al.. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.  J Infect Dis. 2007;  195 (3) 322-329
• 221 Chappuis F. Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go.  Clin Infect Dis. 2007;  45 (11) 1443-1445
• 222 Priotto G, Kasparian S, Mutombo W et al.. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.  Lancet. 2009;  374 (9683) 56-64
• 223 Milord F, Pépin J, Loko L, Ethier L, Mpia B. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness.  Lancet. 1992;  340 (8820) 652-655
• 224 Pépin J, Milord F, Khonde A N et al.. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness.  Trans R Soc Trop Med Hyg. 1995;  89 (1) 92-97
• 225 Mumba Ngoyi D, Lejon V, Pyana P et al.. How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness.  J Infect Dis. 2010;  201 (3) 453-463
• 226 Cha J H, Furie K, Kay J, Walensky R P, Mullins M E, Hedley-Whyte E T. Case records of the Massachusetts General Hospital. Case 39-2006. A 24-year-old woman with systemic lupus erythematosus, seizures, and right arm weakness.  N Engl J Med. 2006;  355 (25) 2678-2689
• 227 Duarte A G, Sattar F, Granwehr B, Aronson J F, Wang Z, Lick S. Disseminated acanthamoebiasis after lung transplantation.  J Heart Lung Transplant. 2006;  25 (2) 237-240
• 228 Gonzalez M M, Gould E, Dickinson G et al.. Acquired immunodeficiency syndrome associated with Acanthamoeba infection and other opportunistic organisms.  Arch Pathol Lab Med. 1986;  110 (8) 749-751
• 229 Vernon S E, Acar B C, Pham S M, Fertel D. Acanthamoeba infection in lung transplantation: report of a case and review of the literature.  Transpl Infect Dis. 2005;  7 (3-4) 154-157
• 230 Deetz T R, Sawyer M H, Billman G, Schuster F L, Visvesvara G S. Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases.  Clin Infect Dis. 2003;  37 (10) 1304-1312
• 231 Denney C F, Iragui V J, Uber-Zak L D et al.. Amebic meningoencephalitis caused by Balamuthia mandrillaris: case report and review.  Clin Infect Dis. 1997;  25 (6) 1354-1358
• 232 Griesemer D A, Barton L L, Reese C M et al.. Amebic meningoencephalitis caused by Balamuthia mandrillaris.  Pediatr Neurol. 1994;  10 (3) 249-254
• 233 Schuster F L, Visvesvara G S. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals.  Int J Parasitol. 2004;  34 (9) 1001-1027
• 234 Chappell C L, Wright J A, Coletta M, Newsome A L. Standardized method of measuring acanthamoeba antibodies in sera from healthy human subjects.  Clin Diagn Lab Immunol. 2001;  8 (4) 724-730
• 235 Huang Z H, Ferrante A, Carter R F. Serum antibodies to Balamuthia mandrillaris, a free-living amoeba recently demonstrated to cause granulomatous amoebic encephalitis.  J Infect Dis. 1999;  179 (5) 1305-1308
• 236 Schuster F L, Glaser C, Honarmand S, Maguire J H, Visvesvara G S. Balamuthia amebic encephalitis risk, Hispanic Americans.  Emerg Infect Dis. 2004;  10 (8) 1510-1512
• 237 Martinez A J. Infection of the central nervous system due to Acanthamoeba.  Rev Infect Dis. 1991;  13 (Suppl 5) S399-S402
• 238 Recavarren-Arce S, Velarde C, Gotuzzo E, Cabrera J. Amoeba angeitic lesions of the central nervous system in Balamuthia mandrillaris amoebiasis.  Hum Pathol. 1999;  30 (3) 269-273
• 239 Schuster F L, Yagi S, Gavali S et al.. Under the radar: Balamuthia amebic encephalitis.  Clin Infect Dis. 2009;  48 (7) 879-887
• 240 Visvesvara G S, Moura H, Schuster F L. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea.  FEMS Immunol Med Microbiol. 2007;  50 (1) 1-26
• 241 Deol I, Robledo L, Meza A, Visvesvara G S, Andrews R J. Encephalitis due to a free-living amoeba (Balamuthia mandrillaris): case report with literature review.  Surg Neurol. 2000;  53 (6) 611-616
• 242 Marciano-Cabral F, Cabral G. Acanthamoeba spp. as agents of disease in humans.  Clin Microbiol Rev. 2003;  16 (2) 273-307
• 243 Martinez A J, Visvesvara G S. Free-living, amphizoic and opportunistic amebas.  Brain Pathol. 1997;  7 (1) 583-598
• 244 Perez M T, Bush L M. Fatal amebic encephalitis caused by Balamuthia mandrillaris in an immunocompetent host: a clinicopathological review of pathogenic free-living amebae in human hosts.  Ann Diagn Pathol. 2007;  11 (6) 440-447
• 245 Healy J F. Balamuthia amebic encephalitis: radiographic and pathologic findings.  AJNR Am J Neuroradiol. 2002;  23 (3) 486-489
• 246 Schuster F L, Honarmand S, Visvesvara G S, Glaser C A. Detection of antibodies against free-living amoebae Balamuthia mandrillaris and Acanthamoeba species in a population of patients with encephalitis.  Clin Infect Dis. 2006;  42 (9) 1260-1265
• 247 Centers for Disease Control and Prevention (CDC) . Balamuthia amebic encephalitis—California, 1999-2007.  MMWR Morb Mortal Wkly Rep. 2008;  57 (28) 768-771
• 248 Asiri S, Ogbunude P O, Warhurst D C. In vitro assessment of susceptibility of Acanthamoeba polyphaga to drugs using combined methods of dye-binding assay and uptake of radiolabelled adenosine.  Int J Parasitol. 1994;  24 (7) 975-980
• 249 Oliva S, Jantz M, Tiernan R, Cook D L, Judson M A. Successful treatment of widely disseminated acanthamoebiasis.  South Med J. 1999;  92 (1) 55-57
• 250 Jung S, Schelper R L, Visvesvara G S, Chang H T. Balamuthia mandrillaris meningoencephalitis in an immunocompetent patient: an unusual clinical course and a favorable outcome.  Arch Pathol Lab Med. 2004;  128 (4) 466-468
• 251 Schuster F L, Guglielmo B J, Visvesvara G S. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri.  J Eukaryot Microbiol. 2006;  53 (2) 121-126
• 252 Schuster F L, Visvesvara G S. Opportunistic amoebae: challenges in prophylaxis and treatment.  Drug Resist Updat. 2004;  7 (1) 41-51
• 253 Prusiner S B. Prions.  Proc Natl Acad Sci U S A. 1998;  95 (23) 13363-13383
• 254 Duffy P, Wolf J, Collins G, DeVoe A G, Streeten B, Cowen D. Letter: Possible person-to-person transmission of Creutzfeldt-Jakob disease.  N Engl J Med. 1974;  290 (12) 692-693
• 255 Ironside J W, Bell J E. Infective dementias.  Panminerva Med. 2007;  49 (4) 209-225
• 256 Brown P, Brandel J P, Preece M, Sato T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era.  Neurology. 2006;  67 (3) 389-393
• 257 Shiga Y, Miyazawa K, Sato S et al.. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease.  Neurology. 2004;  63 (3) 443-449
• 258 Young G S, Geschwind M D, Fischbein N J et al.. Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis.  AJNR Am J Neuroradiol. 2005;  26 (6) 1551-1562
• 259 Parchi P, Giese A, Capellari S et al.. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects.  Ann Neurol. 1999;  46 (2) 224-233
• 260 Collins S J, Sanchez-Juan P, Masters C L et al.. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease.  Brain. 2006;  129 (Pt 9) 2278-2287
• 261 Ironside J W. Variant Creutzfeldt-Jakob disease.  Haemophilia. 2010;  16 (Suppl 5) 175-180
• 262 Llewelyn C A, Hewitt P E, Knight R S et al.. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.  Lancet. 2004;  363 (9407) 417-421
• 263 Wilson K, Ricketts M N. Transfusion transmission of vCJD: a crisis avoided?.  Lancet. 2004;  364 (9433) 477-479
• 264 Wroe S J, Pal S, Siddique D et al.. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report.  Lancet. 2006;  368 (9552) 2061-2067
• 265 Lukic A, Beck J, Joiner S et al.. Heterozygosity at polymorphic codon 219 in variant Creutzfeldt-Jakob disease.  Arch Neurol. 2010;  67 (8) 1021-1023
• 266 Spencer M D, Knight R S, Will R G. First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features.  BMJ. 2002;  324 (7352) 1479-1482
• 267 Zeidler M, Stewart G E, Barraclough C R et al.. New variant Creutzfeldt-Jakob disease: neurological features and diagnostic tests.  Lancet. 1997;  350 (9082) 903-907
• 268 Zeidler M, Johnstone E C, Bamber R W et al.. New variant Creutzfeldt-Jakob disease: psychiatric features.  Lancet. 1997;  350 (9082) 908-910
• 269 Cordery R J, Alner K, Cipolotti L et al.. The neuropsychology of variant CJD: a comparative study with inherited and sporadic forms of prion disease.  J Neurol Neurosurg Psychiatry. 2005;  76 (3) 330-336
• 270 Collie D A, Summers D M, Sellar R J et al.. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases.  AJNR Am J Neuroradiol. 2003;  24 (8) 1560-1569
• 271 Zeidler M, Sellar R J, Collie D A et al.. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease.  Lancet. 2000;  355 (9213) 1412-1418
• 272 Green A J, Thompson E J, Stewart G E et al.. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease.  J Neurol Neurosurg Psychiatry. 2001;  70 (6) 744-748
• 273 Will R G, Zeidler M, Stewart G E et al.. Diagnosis of new variant Creutzfeldt-Jakob disease.  Ann Neurol. 2000;  47 (5) 575-582
• 274 Hill A F, Butterworth R J, Joiner S et al.. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples.  Lancet. 1999;  353 (9148) 183-189
• 275 Wadsworth J D, Joiner S, Hill A F et al.. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay.  Lancet. 2001;  358 (9277) 171-180
• 276 Ironside J W, Head M W, Bell J E, McCardle L, Will R G. Laboratory diagnosis of variant Creutzfeldt-Jakob disease.  Histopathology. 2000;  37 (1) 1-9
• 277 Will R G, Ironside J W, Zeidler M et al.. A new variant of Creutzfeldt-Jakob disease in the UK.  Lancet. 1996;  347 (9006) 921-925